Newsroom

Sorted by: Latest

-

Capital One Completes Acquisition of Discover

MCLEAN, Va.--(BUSINESS WIRE)--Capital One Financial Corporation (NYSE: COF) today announced that it has completed its acquisition of Discover Financial Services. “This deal brings together two innovative, mission-driven companies that together are poised to deliver breakthrough products and experiences to consumers, businesses, and merchants,” said Richard D. Fairbank, Founder and CEO of Capital One. “I am particularly grateful for the leadership and partnership of Discover’s Board of Directors...
-

SANA截止日期:Rosen Law Firm敦促亏损超过10万美元的Sana Biotechnology, Inc.(NASDAQ:SANA)投资者联系该所以了解有关其权利的信息

纽约--(BUSINESS WIRE)--(美国商业资讯)-- 全球投资者权益律师事务所Rosen Law Firm提醒投资者,一名股东代表在2023年3月17日至2024年11月17日期间购买Sana Biotechnology, Inc.(NASDAQ:SANA)证券的投资者提起集体诉讼。Sana是一家生物技术公司。 如需了解更多信息,请提交表格,向Phillip Kim律师发送电子邮件或致电866-767-3653联系我们。 指控内容:Rosen Law Firm正在调查有关Sana Biotechnology, Inc. (NASDAQ: SANA)在业务运营方面误导投资者的指控。 起诉书称,在集体诉讼期间,被告作出了虚假和/或误导性陈述和/或未能披露以下事实: (1) Sana面临资金不足,无法维持当前运营和推进一个或多个候选产品的的重大风险;(2) SC291(肿瘤学领域)、SC379和SG299的实际前景不如被告方此前向投资者所宣称的那样乐观;(3) 为了保留现金和推进更有前景的候选产品,Sana可能会减少对SC291(肿瘤学领域)、SC379和SG299的资助和/或停止...
-

Tornado Recovery: U-Haul Offers 30 Days Free Storage in 3 States

ST. LOUIS--(BUSINESS WIRE)--U-Haul® has made 24 Company stores across three states available to help storm victims with 30 days of free self-storage and U-Box® container usage after a powerful weather system spawned a number of deadly tornadoes on Friday. The tornadoes tore through homes — and in some cases communities — while being responsible for more than 20 casualties, according to news reports. Many families remain without power and face a long rebuilding process. While St. Louis and other...
-

SANA Deadline: Rosen Law Firm Urges Sana Biotechnology, Inc. (NASDAQ: SANA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers and acquirers of Sana Biotechnology, Inc. (NASDAQ: SANA) securities between March 17, 2023 and November 17, 2024. Sana is a biotechnology company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Sana Biotechnology, In...
-

Fujirebio erhält Marktzulassung für In-vitro-Diagnosetest Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio zur Unterstützung der Identifizierung von Patienten mit Amyloidpathologie bei Alzheimer

MALVERN, Pennsylvania, USA, und TOKIO--(BUSINESS WIRE)--Wie Fujirebio heute mitteilte, hat die US-amerikanische Arzneimittelbehörde FDA (Food and Drug Administration) die 510(k)-Zulassung für den Lumipulse ® G pTau 217/β-Amyloid 1-42 Plasma Ratio In-vitro-Diagnosetest (IVD) erteilt. Der Test ermöglicht die Beurteilung der Amyloidpathologie bei Patienten, die auf Alzheimer-Krankheit und andere Ursachen eines kognitiven Verfalls untersucht werden, und wurde von der FDA als „Breakthrough Device De...
-

Samenvatting: Fujirebio ontvangt marketinggoedkeuring voor Lumipulse® G pTau 217/β-amyloïde in-vitrodiagnostische test met plasmaverhouding van 1-42 als hulpmiddel bij het identificeren van patiënten met amyloïdepathologie geassocieerd met de ziekte van Alzheimer

MALVERN, Pa., & TOKYO--(BUSINESS WIRE)--Fujirebio heeft vandaag aangekondigd dat de Amerikaanse Food and Drug Administration (FDA) 510(k) goedkeuring heeft verleend voor de Lumipulse ® G pTau 217/β-Amyloid in-vitro diagnostische (IVD) test met plasmaverhouding van 1-42 van het bedrijf voor de beoordeling van amyloïde pathologie bij patiënten die worden onderzocht op de ziekte van Alzheimer en andere oorzaken van cognitieve achteruitgang. Deze bekendmaking is officieel geldend in de originele br...
-

ZYXI截止日期:Rosen Law Firm敦促损失超过10万美元的Zynex, Inc. (NASDAQ: ZYXI)投资者与律所联系以了解有关其权利的信息

纽约--(BUSINESS WIRE)--(美国商业资讯)-- 全球性投资者权益律师事务所Rosen Law Firm提醒投资者,一名股东代表在2023年3月13日至2025年3月11日期间购买Zynex, Inc. (NASDAQ: ZYXI)证券的投资者提起了集体诉讼。Zynex是一家医疗器械制造商。 如需了解更多信息,请提交表格、向Phillip Kim律师发送电子邮件,或致电866-767-3653联系我们。 指控内容:Rosen Law Firm正在调查对Zynex, Inc. (NASDAQ: ZYXI)在其业务运营方面误导投资者的指控。 起诉书指称,在整个集体诉讼期间,被告未能向投资者告知以下事实:(1) Zynex存在超额发货行为(包括电极片等产品);(2)由于这一行为,Zynex虚增了收入;(3) Zynex提交虚假理赔申请的做法引发了包括Tricare在内的保险公司的审查;(4)因此,Zynex很可能面临不利后果,包括被移出保险公司网络及受到联邦政府处罚;以及(5)由于上述原因,被告关于Zynex的业务、运营和前景的正面陈述具有重大误导性和/或缺乏合理依据。 现在怎...
-

ZYXI截止日期:Rosen Law Firm敦促損失超過10萬美元的Zynex, Inc. (NASDAQ: ZYXI)投資人與法律事務所聯絡以瞭解有關其權利的資訊

紐約--(BUSINESS WIRE)--(美國商業資訊)-- 全球性投資人權益法律事務所Rosen Law Firm提醒投資人,一名股東代表在2023年3月13日至2025年3月11日期間購買Zynex, Inc. (NASDAQ: ZYXI)證券的投資人提起了集體訴訟。Zynex是一家醫療器材製造商。 如欲瞭解更多資訊,請遞交表格、向Phillip Kim律師寄送電子郵件,或致電866-767-3653聯絡我們。 指控內容:Rosen Law Firm正在調查對Zynex, Inc. (NASDAQ: ZYXI)在其業務營運方面誤導投資人的指控。 起訴書指稱,在整個集體訴訟期間,被告未能向投資人告知以下事實:(1) Zynex存在超額出貨行為(包括電極片等產品);(2)由於這一行為,Zynex虛增了收入;(3) Zynex遞交虛假理賠申請的做法引發了包括Tricare在內的保險公司的審查;(4)因此,Zynex很可能面臨不利後果,包括被移出保險公司網路及受到聯邦政府處罰;以及(5)由於上述原因,被告關於Zynex的業務、營運和前景的正面陳述具有重大誤導性和/或缺乏合理依據。 現在怎...
-

Clover Expands Commitment to the Restaurant Industry with the Launch of Clover Hospitality by BentoBox

CHICAGO--(BUSINESS WIRE)--Clover, the world's smartest point-of-sale solution, under parent company, Fiserv, today announced the launch of Clover Hospitality by BentoBox at the 2025 National Restaurant Association (NRA) Show in Chicago, with a bold commitment to the industry and new tagline, There’s a Clover for Every Restaurant. The solution, complete with new-to-market features designed to enhance the guest experience, marks an exciting step forward as Clover – already serving more than 125,0...
-

Fujirebio reçoit une autorisation de mise sur le marché pour le test de diagnostic in vitro Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio en tant qu’aide à l’identification des patients atteints de pathologie amyloïde associée à la maladie...

MALVERN, Pennsylvanie, et TOKYO--(BUSINESS WIRE)--  Fujirebio reçoit une autorisation de mise sur le marché pour le test de diagnostic in vitro Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio en tant qu’aide à l’identification des patients atteints de pathologie amyloïde associée à la maladie d’Alzheimer Fujirebio annonce aujourd’hui que la Food and Drug Administration (FDA) des États-Unis a accordé l’autorisation 510(k) pour son test de diagnostic in vitro Lumipulse ® G pTau 217/β-Amyloid 1...